Method for detecting NANBV associated seroconversion
AssigneesBioprocess Pty Ltd., P. Hoffmann-La Roche, Ltd.
InventorsSuzanne Zebedee, Genevieve Inchauspe, Marc S. Nasoff, Alfred M Prince
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.
Claims20
A method for detecting seroconversion associated with NANBV infection at early times after infection with an essentially pure and isolated NANBV capsid antigen comprising:
- (a) initiating an immunoreaction by contacting a body fluid sample with an essentially pure and isolated NANBV capsid antigen;
- (b) maintaining said immunoreaction for a time period sufficient for allowing antibodies against the NANBV capsid antigen present in the body fluid sample to immunoreact with said NANBV capsid antigen to form an immunoreaction product;
- and
- (c) detecting the presence of said immunoreaction product formed and thereby detecting early seroconversion.
A method for detecting seroconversion associated with NANBV infection at early times after infection with an essentially pure and isolated NANBV capsid antigen and thereby reducing the number of body fluid samples erroneously characterized as non-reactive in the testing of human body fluid for NANBV hepatitis antibody by employing for each body fluid sample, in a plurality of said samples from different subjects, a method comprising:
- (a) initiating an immunoreaction by contacting each said body fluid sample with an essentially pure and isolated NANBV capsid antigen;
- (b) maintaining said immunoreaction for a time period sufficient for allowing antibodies against the NANBV capsid antigen present in each body fluid sample to immunoreact with said NANBV capsid antigen to form an immunoreaction product;
- and
- (c) detecting the presence of said immunoreaction product formed and early seroconversion, thereby reducing the number of body fluid samples in said plurality of samples erroneously characterized as non-reactive.
A method for detecting seroconversion associated with NANBV infection at early times after infection comprising:
- (a) initiating an immunoreaction by contacting a body fluid sample with a pure and isolated NANBV capsid antigen and full length C-100-3 antigen;
- (b) maintaining said immunoreaction for a time period sufficient for allowing antibodies against said NANBV capsid and C-100-3 antigens present in said body fluid sample to immunoreact with said NANBV capsid and C-100-3 antigens to form immunoreaction products;
- and
- (c) detecting the presence of any of said immunoreaction products formed and thereby detecting early seroconversion and reducing the risk of a false negative relative to the results of performing the same assay using only said C-100-3 antigen.
A method for detecting seroconversion associated with NANBV infection at early times after infection comprising:
- (a) initiating an immunoreaction by contacting a body fluid sample with a pure and isolated NANBV capsid antigen having the amino acid sequence from residue 1 to 120 of SEQ ID NO:
- 73 and full length C-100-3 antigen;
- (b) maintaining said immunoreaction for a time period sufficient for allowing antibodies against said NANBV capsid and C-100-3 antigens present in the body fluid sample to immunoreact with said NANBV capsid and C-100-3 antigens to form immunoreaction products;
- and
- (c) detecting the presence of any said immunoreaction products formed and thereby detecting early seroconversion and reducing the risk of false negative relative to the results of performing the same assay using only said C-100-3 antigen.
A method for detecting seroconversion associated with NANBV infection at early times after infection and thereby reducing the number of body fluid samples erroneously characterized as non-reactive in the testing of human body fluid for NANBV hepatitis antibody by employing for each body fluid sample, in a plurality of said samples from different subjects, a method comprising:
- (a) initiating an immunoreaction by contacting each said body fluid sample with a pure and isolated NANBV capsid antigen and full length C-100-3 antigen;
- (b) maintaining said immunoreaction for a time period sufficient for allowing antibodies against the NANBV capsid C-100-3 antigens present in each body fluid sample to immunoreact with said NANBV capsid and C-100-3 antigens to form an immunoreaction product;
- and
- (c) detecting the presence of any of said immunoreaction product formed and early seroconversion,
- thereby reducing the number of body fluid samples in said plurality of samples erroneously characterized as non-reactive relative to the results of performing the same assays using only said C-100-3 antigen.
Dependencies are inferred from the claim text.